Neoplasms

All Conditions

Rare Diseases

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Patients will be treated with the standard surgical therapy - glioma resection.

Glioma resection

Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.

Blood sampling

Tamara Lah Turnšek, PhD

Primož Rožman, MD, PhD

Matija Veber, dipl. biotech.

Marjan Koršič, MD, PhD

Kristina Gruden, PhD

Study on glioma patients treated with brain surgery is focusing on the analysis of their transcriptome expression profile measured in two immune cell populations, CD4+ T cells and CD56+ NK cells. The results of analysis will be compared to the reference data of healthy population. Furthermore, the metabolomic and immunological status will also be monitored and compared to healthy group reference data, before and after the surgery\*. With comparative crossomics analysis the investigators intend to possibly identify new diagnostic and prognostic biological markers for the relapse of the disease. The results are expected to convey a deeper insight into pathophysiology of the glioma as well as into the mechanisms of the current surgical therapy.

\* The healthy reference data have been published in collaborative efforts of BTC, UMC and NIB (Gruden et al. 2012).

Whole blood, blood plasma, peripheral blood mononuclear cells, CD4+ T cells, CD56+ NK cells

Gene Expression, Immunological Status and Metabolome in Glioma Patients

Monitoring and Analysis of Gene Expression, Immunological Status and Metabolome in Peripheral Blood Mononuclear Cells and Their Specific Subpopulations (CD4+ T Cells and CD56+ NK Cells) in Surgically Treated Glioma Patients

Blood Transfusion Centre of Slovenia

University Medical Centre Ljubljana

National Institute of Biology, Slovenia

Director of the National Institute of Biology, Slovenia

Digestive System Diseases

Gland and Hormone Related Diseases

Carcinoma

Adenocarcinoma

Pancreatic Neoplasms

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Patients with pancreatic tubular adenocarcinoma

Observation

Borut Stabuc, MD, PhD

Lojze Smid, MD

Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.

Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer

Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma

Primoz Rozman MD, PhD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Gene Expression, Immunological Status and Metabolome in Glioma Patients	NCT01525459	Glioma	Glioma resectio... Blood sampling	20 Years - 80 Years	National Institute of Biology, Slovenia
Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer	NCT00947102	Pancreatic Tubu...	Observation	30 Years - 85 Years	Blood Transfusion Centre of Slovenia
Gene Expression, Immunological Status and Metabolome in Glioma Patients	NCT01525459	Glioma	Glioma resectio... Blood sampling	20 Years - 80 Years	National Institute of Biology, Slovenia

Spots Global Cancer Trial Database for immunological status